Lisle M. Nabell
YOU?
Author Swipe
View article: Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Figure S1: OPSCC EGFR H-scores.
View article: Supplementary Table S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Table S1: Patient demographics.
View article: Supplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Table S2: Surgeon survey assessing the value of fluorescence imaging during the procedure.
View article: Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
View article: Supplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
View article: Supplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
View article: Supplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Video S1: Late-resection intraoperative brightfield and robot fluorescence views of representative OPSCC cases.
View article: Data from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Data from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Purpose:The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has continually increased during the past several decades. Using transoral robotic surgery (TORS) significantly improves functional outcomes relative to open surgery fo…
View article: Supplementary Table S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Table S1: Patient demographics.
View article: Supplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Table S3: Representativeness of Study Participants.
View article: Supplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
View article: Supplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Table S3: Representativeness of Study Participants.
View article: Data from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Data from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Purpose:The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has continually increased during the past several decades. Using transoral robotic surgery (TORS) significantly improves functional outcomes relative to open surgery fo…
View article: Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
View article: Supplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
View article: Supplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Video S1: Late-resection intraoperative brightfield and robot fluorescence views of representative OPSCC cases.
View article: Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Figure S1: OPSCC EGFR H-scores.
View article: Supplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer Open
Supplementary Table S2: Surgeon survey assessing the value of fluorescence imaging during the procedure.
View article: Supplementary Table S10 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S10 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S10. Serum PK Parameters of Tab at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S3 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S3 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S3. SLITRK6 Expression Levels, H-Score: Parts A, B, and C, Expansion Phase (FAS)
View article: Supplementary Table S11 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S11 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S11. Statistical Assessment of Dose Proportionality for ADC, Power Model, PK Analysis Set
View article: Supplementary Figure S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Figure S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Figure S2. PFS, 1.00 mg/kg vs Total Study Population and CPIExposed Population (Parts A, B, and C, FAS)
View article: Supplementary Table S10 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S10 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S10. Serum PK Parameters of Tab at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S2. Representativeness of Study Participants
View article: Supplementary Table S8 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S8 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S8. Serum PK Parameters of MMAE at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S4 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S4 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S4. TEAEs (≥10% Patients) by SOC and PT: Part A, Escalation Phase
View article: Supplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S9. Serum PK Parameters of TAb at Cycle 1, Day 1, PK Analysis Set
View article: Supplementary Table S1 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S1 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S1. Inclusion Criteria Details for Parts A, B, and C
View article: Supplementary Table S7 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S7 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S7. Serum PK Parameters of MMAE at Cycle 1, Day 1, PK Analysis Set
View article: Supplementary Table S6 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S6 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S6. Serum PK Parameters of AGS15E ADC at Cycle 1, Day 15, PK Analysis Set